Fintel said on May 9, 2023, Oppenheimer repeated a report in Editas Medicine (NASDAQ:EDIT), execution recommendation.
Analyst Price Forecast Suggests 36.59% Gain
As of April 24, 2023, Editas Medicine’s average price target for the year is 13.14. Predictions range from a low of $7.07 to a high of $31.50. The average price target represents a 36.59% increase from the latest reported closing price of 9.62.
Check out our leaderboard of companies with the biggest price target upside.
Editas Medicine’s projected annual revenue is 20 million, down 12.89%. Projected full-year non-GAAP EPS is -3.33.
What is Fund Sentiment?
Editas Medicine has 440 foundations or institutions reporting positions. This is a decrease of 14 owners or 3.08% over the previous quarter.Portfolio average weight of all funds EDIT only was 0.05%, a decrease of 4.52%. The total number of shares owned by the institution increased by 12.77% to 58,698,000 shares in the last three months. 
EDIT’s put/call ratio is 0.24, indicating a bullish outlook.
What are other shareholders doing?
The XBI – SPDR(R) S&P(R) Biotech ETF holds 7,446,000 shares representing a 10.79% ownership interest in the company. In previous filings, the company reported he owned 4,798,000 shares. will increase 35.57%.office decreased Portfolio allocation in EDIT increased by 4.28% last quarter.
VTSMX – Vanguard Total Stock Market Index Fund Investor Shares holds 2,161,000 shares representing a 3.13% ownership interest in the company. In previous filings, the company reported he owned 2,112,000 shares. will increase 2.28%.office decreased Last quarter’s EDIT portfolio allocation increased by 31.52%.
Millennium Management holds 2,142,000 shares representing 3.11% of the company’s ownership. In previous filings, the company reported he owned 1,883,000 shares. will increase 12.12%.office gain EDIT portfolio allocation increased by 16,668.92% last quarter.
Woodline Partners owns 2,079,000 shares representing a 3.01% ownership interest in the company. In previous filings, the company reported that it owned 0,000 shares of him. will increase 100.00%.
NAESX – Vanguard Small-Cap Index Fund Investor Shares holds 1,772,000 shares representing a 2.57% ownership interest in the company. In previous filings, the company reported he owned 1,747,000 shares. will increase of 1.41%.office decreased Last quarter’s EDIT portfolio allocation increased by 31.95%.
Editorial background information in medicine
(This description is provided by the company.)
Editas Medicine, a leading genome-editing company, is committed to unleashing the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into robust, robust medicines for people suffering from serious diseases around the world. We are focused on transforming it into our therapeutic pipeline. Editas Medicine seeks to discover, develop, manufacture and commercialize innovative, durable and precision genomic medicines for a wide variety of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com.
View all of Editas Medicine’s regulatory filings.
This story was originally published in Fintel.
The views and opinions expressed herein are those of the authors and do not necessarily reflect those of Nasdaq, Inc.